BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

711 related articles for article (PubMed ID: 27144434)

  • 1. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.
    Simões AE; Pereira DM; Gomes SE; Brito H; Carvalho T; French A; Castro RE; Steer CJ; Thibodeau SN; Rodrigues CM; Borralho PM
    Cell Death Dis; 2015 Apr; 6(4):e1718. PubMed ID: 25855966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53.
    Borralho PM; Moreira da Silva IB; Aranha MM; Albuquerque C; Nobre Leitão C; Steer CJ; Rodrigues CM
    Biochim Biophys Acta; 2007 Jan; 1772(1):40-7. PubMed ID: 17056233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
    Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
    Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53.
    Chan JY; Phoo MS; Clement MV; Pervaiz S; Lee SC
    Cancer Biol Ther; 2008 Aug; 7(8):1305-12. PubMed ID: 18497562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERK5 activation is essential for osteoclast differentiation.
    Amano S; Chang YT; Fukui Y
    PLoS One; 2015; 10(4):e0125054. PubMed ID: 25885811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
    Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
    Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.
    Wang H; Zhang L; Yang X; Jin Y; Pei S; Zhang D; Zhang H; Zhou B; Zhang Y; Lin D
    Oncotarget; 2015 Jun; 6(16):14385-98. PubMed ID: 25965911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
    Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M
    Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.
    Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy.
    Sui X; Kong N; Wang X; Fang Y; Hu X; Xu Y; Chen W; Wang K; Li D; Jin W; Lou F; Zheng Y; Hu H; Gong L; Zhou X; Pan H; Han W
    Sci Rep; 2014 Apr; 4():4694. PubMed ID: 24733045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to 5-fluorouracil via HSP90/Src-mediated increase in thymidylate synthase expression in colon cancer.
    Ahn JY; Lee JS; Min HY; Lee HY
    Oncotarget; 2015 Oct; 6(32):32622-33. PubMed ID: 26416450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic signaling of MEK5-ERK5.
    Hoang VT; Yan TJ; Cavanaugh JE; Flaherty PT; Beckman BS; Burow ME
    Cancer Lett; 2017 Apr; 392():51-59. PubMed ID: 28153789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-FU targets rpL3 to induce mitochondrial apoptosis via cystathionine-β-synthase in colon cancer cells lacking p53.
    Pagliara V; Saide A; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Russo G; Russo A
    Oncotarget; 2016 Aug; 7(31):50333-50348. PubMed ID: 27385096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
    Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
    Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells.
    Can G; Akpinar B; Baran Y; Zhivotovsky B; Olsson M
    Oncogene; 2013 Sep; 32(38):4529-38. PubMed ID: 23108402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.
    Oliver Metzig M; Fuchs D; Tagscherer KE; Gröne HJ; Schirmacher P; Roth W
    Oncogene; 2016 Jun; 35(26):3399-409. PubMed ID: 26522725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.